The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Cereblon and GSPT1 degrader in refractory/relapsed AML
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, outlines the Phase I, dose-escalation and expansion, first-in-human clinical study (NCT02848001) of CC-90009 in patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
